PRECISELY ENGINEERING THE FUTURE OF OPHTHALMOLOGYTM

ABOUT ENVISIA THERAPEUTICS™

envisia1In 2013, Liquidia Technologies formed a new company, Envisia Therapeutics,™ to develop novel therapeutics that can address critical unmet needs in ophthalmology.

OPHTHALMOLOGY PROGRAMS

opthalmology2As many as 285 million people suffer from disease-related visual impairments and blindness, but an estimated 80 percent of these visual impairments are actually preventable.

PRINT® TECHNOLOGY

technology2The PRINT® technology is a proprietary system capable of engineering highly precise microparticle and nanoparticle systems.

ANNOUNCEMENTS

ENVISIA THERAPEUTICS TO PRESENT AT GLAUCOMA 360 CONFERENCE

February 4th, 2014

Company Provides First Glimpse Into ENV515 Glaucoma Program RESEARCH TRIANGLE PARK, NC – February 4, 2014 – Envisia Therapeutics today announced that it will present initial................READ MORE

ENVISIA THERAPEUTICS DEBUTS WITH $25 MILLION SERIES A FINANCING

November 11th, 2013

Transformative New Ophthalmology Company Licenses Technology from Liquidia RESEARCH TRIANGLE PARK, NC– November 12, 2013 – Envisia Therapeutics, a new biotechnology company formed by Liquidia Technologies,................READ MORE

LIQUIDIA ANNOUNCES PLAN TO FORM OPHTHALMOLOGY COMPANY TO SUPPORT PRODUCT DEVELOPMENT STRATEGY

April 23rd, 2013

NewCo Strategy Places Focus on Unmet Needs in High Growth Therapeutic Areas RESEARCH TRIANGLE PARK, NC– May 02, 2013 – Liquidia Technologies today announced its intent................READ MORE

Twitter

Copyright 2013 Envisia Therapeutics